Key facts
- Lumicell’s last known valuation is $241.0M (Jul 2024).
- It has raised $333.3M across 8 recorded rounds; the latest was Later Stage VC ($198.1M) in Apr 2025.
- Notable investors include US National Science Foundation, Kinled Holding, Claridge Venture Partners, BlueIO, Burch Creative Capital — 14 tracked in total.
- Lumicell has filed 9 Form Ds with the SEC since 2014, most recently May 2025 ($198.1M sold to 64 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Lumicell
Funding rounds
8 roundsAbout Lumicell
Developer of oncology surgical devices designed to improve the way cancer surgery is performed. The company's devices use an optical contrast agent that targets the tumor microenvironment to fluoresce near cancer cells at the tumor margin along with a single-cell resolution imaging device to fit into the lumpectomy cavity and scan for residual cancer at the margins, enabling surgeons to remove cancer cells in the cavity walls in real-time during surgery.
- Sector
- Healthcare
- HQ
- Newton, MA, United States
- Founded
- 2008
- Employees
- 59
- Website
- lumicell.com/
- Ownership
- Privately Held (backing)
Lumicell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lumicell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lumicell in its N-PORT filings yet. We sweep new filings monthly.